HIV Positive patient in remission following breakthrough medical trial

A new medical trial had a grand breakthrough when one of the patients who was HIV Positive tested negative for the virus.

HIV breakthrough a female presenting person works in a science lab

A man with HIV has gone into remission after taking part in a breakthrough medical study.

The 34 year-old Brazilian man was first diagnosed with HIV in 2012. He was given a treatment of antiretroviral therapy along with a host of other medications for 48 weeks.

57 weeks later HIV DNA could not be found in his cells and his HIV tests were also coming back negative.

Despite this breakthrough, experts told PinkNews that they were only wearily calling it a “cure” for HIV.

Dr Andrea Savarino of the Institute of Health in Italy told the U.K. AIDS organization Aidsmap that this case was extremely interesting and it may boost further research for a cure.

“The antibody response decreased over time if the antibody decreases, it is possible that the virus has stopped its repetition,” he said.

“The result is highly likely not to be reproducible,” he added, before describing the case as “preliminary” result. The other four patients did not rebound.

This is not the first time someone who previously tested positive for HIV has gone into remission. Twelve years ago, the ‘Berlin patient’ went into remission after receiving a bone marrow transplant to treat leukaemia.

Since then, a London man has also gone into remission due to a bone marrow transplant.

Meanwhile, a new drug for HIV Positive people was approved by the US Food and Drug Administration. The medication is intended to combat drug resistance in “heavily treatment-experienced” HIV Positive people, according to the drug maker ViiV.

The drug – fostemsavir – is used in combination with other antiretroviral medicines to help those whose treatments are not working either because of intolerance, safety or resistance.

“There is a small group of heavily treatment-experienced adults living with HIV who are not able to maintain viral suppression with currently available medication and, without effective new options, are at great risk of progressing to AIDS,” Deborah Waterhouse, CEO of ViiV, said.

© 2020 GCN (Gay Community News). All rights reserved.

Support GCN

GCN has been a vital, free-of-charge information service for Ireland’s LGBT+ community since 1988.

During this global COVID pandemic, we like many other organisations have been impacted greatly in the way we can do business and produce. This means a temporary pause to our print publication and live events and so now more than ever we need your help to continue providing this community resource digitally.

GCN is a registered charity with a not-for-profit business model and we need your support. If you value having an independent LGBT+ media in Ireland, you can help from as little as €1.99 per month. Support Ireland’s free, independent LGBT+ media.

0 comments. Please sign in to comment.